

Subject Index

A

ABANDONED ASSETS 2.34–35

ABANDONMENT OF R&D EFFORTS

- Factors to consider in determination of 4.25
- Generally 4.24–29
- Impact of decision to abandon R&D efforts on recognition and measurement 2.67
- When to test indefinite-lived IPR&D assets for impairment 4.14

ACQUIRED IPR&D PROJECTS

- Attributes of 2.16–17
- Incompleteness criteria 2.17
- Substance criteria 2.17

ACQUISITIONS OF ASSETS. *See* asset acquisitions

ACTIVE MARKETS 6.04

ALTERNATIVE FUTURE USE 3.13–27

AMORTIZATION

- Assets acquired for use in R&D activities 3.29
- Assets resulting from R&D activities 4.43–50
- Contributory asset charges 6.97
- Indefinite-lived IPR&D assets 4.07
- IPR&D assets 6.122–131
- Methods 4.43–43
- Methods, changes in 4.50
- Tax amortization benefits (TAB). *See* tax amortization benefits

APPLIED RESEARCH PHASE 2.45

ASSET ACQUISITIONS 3.01–31

- Accounting after 3.11
- Accounting for assets acquired in 3.01–31
- Acquisition date recognition of consideration exchanged 3.11
- Additional considerations 4.83–86
- In business combinations. *See* business combinations, assets acquired in
- Considerations for disclosures 5.08–12
- Contingencies acquired in 3.10
- Contingent consideration 3.10
- Goodwill 3.10
- IPR&D assets 6.02
- Sample footnote disclosures 5.10
- Transaction costs 3.10
- For use in R&D activities. *See* assets acquired for use in R&D activities

ASSETS

- Acquisitions. *See* asset acquisitions
- Alternative future use 3.13–27
- Contributory 6.85–89
- Cost determination 3.11
- Defensive. *See* defensive assets

ASSETS—continued

- Deferred tax 4.82
- Exploitation rights 3.30
- Fixed. *See* fixed assets
- Held and used. *See* held and used assets
- Held for sale. *See* held for sale assets
- Identifiable 2.07
- Idled 2.10
- Indefinite-lived IPR&D. *See* indefinite-lived IPR&D assets
- In-process R&D (IPR&D). *See* in-process R&D assets
- Intangible. *See* intangible assets
- Nonfinancial. *See* nonfinancial assets
- Not used in R&D activities 2.11–13
- Outlicensed 2.10
- Primary 4.65
- Recognition 2.06–07
- Required rate of return on 6.94
- Resulting from R&D activities. *See* assets resulting from R&D activities
- Return on. *See* weighted average return on assets (WARA)
- Summary 6.199, Schedule 6-11
- Tangible
 - Temporarily idled or abandoned 2.34–35
 - That contribute to generation of cash flows 6.82–98
 - Used in R&D activities. *See* assets used in R&D activities

ASSETS ACQUIRED FOR USE IN R&D ACTIVITIES

- Accounting after acquisition 3.11
- Acquisition date recognition of consideration exchanged 3.11
- Alternative future use 3.13–27
- Cost allocation 3.11
- Cost determination 3.11
- Definition 3.08
- Disclosures 5.01–12
- Income tax considerations 4.80–82
- Initial recognition 3.10
- Sample footnote disclosures 5.04
- Subsequent accounting 4.01–86
- Useful life and amortization 3.29

ASSETS ACQUIRED IN BUSINESS

COMBINATIONS 2.01–68

- Accounting for 3.10
- Definition of 2.01–68
- Description of 2.05
- Disclosures 5.01–07
- Intangible 4.02–79
- Not used in R&D activities 2.11–13
- Recognition 2.06–15
- Subsequent accounting for 4.02–79
- Unit of account 2.18–24
- Used in R&D activities 2.08–10
- Useful lives of 3.10

ASSETS RESULTING FROM R&D ACTIVITIES

- Accounting for 4.07, 4.08, 4.32–53
- Amortization 4.43–50
- Generally 2.12
- Held and used 4.54–73
- Impairment testing of 4.51–73
- Useful life of 4.37–42

ASSETS USED IN R&D

- ACTIVITIES 2.08–10**
- Completed intangible 2.36–37
- Criteria for 3.30
- Generally 2.08–10
- Tangible 2.38

B**BASE TECHNOLOGY 6.58****BUSINESS COMBINATIONS, ASSETS**

- ACQUIRED IN 2.01–68**
- Accounting for 3.10
- Contingent considerations 3.10
- Definition of 2.01–68
- Description of 2.05
- Disclosures 5.01–07
- Intangible 4.02–79
- Not used in R&D activities 2.11–13
- Recognition 2.06–15
- Subsequent accounting for 4.02–79
- Unit of account 2.18–24
- Used in R&D activities 2.08–10
- Useful lives of 3.10

BUSINESS ENTERPRISE**VALUATION 6.199, Schedule 6-10****C****CAPITAL**

- Weighted average cost of capital (WACC) 6.95, 6.115, 6.120
- Working 6.35, 6.86, 6.94

CAPITAL CHARGES. See contributory asset charges**CASH FLOWS**

- After-tax 6.148–149
- Assets that contribute to generation of 6.82–98
- Conditional 6.37
- Economic 6.39–41
- Future 4.60–68, 4.64
- Present value 6.99–121

COLLABORATIVE ARRANGEMENTS 2.10**COMPANY HISTORY 6.38****COMPETITIVE POSITION 6.38****CONCEPTUALIZATION PHASE 2.45****CONDITIONAL CASH FLOWS 6.37****CONTINGENCIES 3.10****CONTINGENT CONSIDERATION 3.10****CONTRIBUTORY ASSET CHARGES**

- Assets that contribute to generation of cash flows 6.82–98
- Basis for determining charges 6.90–95
- Contribution for elements of goodwill 6.96
- Examples 6.94
- Generally 1.20, 6.82
- Period of charge 6.97
- Tax amortization benefit 6.97
- Valuation example 6.199, Schedule 6-8

CONTRIBUTORY ASSETS

- Examples 6.86
- Types of 6.85–89

CORE TECHNOLOGY 2.25–28, 6.58**COST APPROACH TO FAIR VALUE OF IPR&D ASSETS**

- Applications 1.04
- Generally 1.06–09, 6.178
- Items to include in valuation report 6.177

COSTS

- Accounting guidance 3.12
- Allocating 3.11
- Current replacement cost 1.06
- Determining 3.11
- Intangible assets purchased from others 3.12
- Materials, equipment, and facilities 3.12
- R&D 3.12
- Transaction 3.10
- Weighted average cost of capital (WACC) 6.95

COSTS OF SALES 6.35**CURRENT REPLACEMENT COST 1.06****CUSTOMER LISTS 6.94****CUSTOMER RELATIONSHIPS 6.191–192, 6.199, Schedule 6-4****D****DECISION TO ABANDON R&D****EFFORTS 2.67****DECISION TREE ANALYSIS**

- Generally 1.25–26, 6.154
- IPR&D assets 6.154–170, 6.182
- Items to include in valuation report 6.182
- Pharmaceutical IPR&D example ... 6.155–168
- Summary 6.169–170

DEFENSIVE ASSETS

- Definition of 2.10
- IPR&D assets 2.29–33, 6.19–25

DEFENSIVE INTANGIBLE ASSETS 2.30**DEFERRED TAX ASSETS AND****LIABILITIES 4.82****DEVELOPED PRODUCT TECHNOLOGY**

- Definition of 6.62
- Generally 6.59
- Royalty payments 1.22

DEVELOPED PRODUCT**TECHNOLOGY—continued**

- Valuation example 6.193–1945,
..... 6.199, Schedule 6-5

DEVELOPMENT

- Early development
 phase Exhibit 2-1 at 2.68
- Phases of Exhibit 2-1 at 2.68
- Project phase 2.45

DISCLOSURES

- Assets acquired for use in R&D
 activities 5.01–12

DISCOUNT RATE

- Calculation of after-tax cash flow present
 value 6.148–149
- Calculation of cash flow present
 value 6.99–121
- Generally 6.99
- Selection 6.100, 6.148–149

DISCOUNT RATE ADJUSTMENT TECHNIQUE

(DRAT) 6.02, 6.100–111

DISCOUNTED CASH FLOW METHOD 1.15**DISCOVERY RESEARCH****PHASE Exhibit 2-1 at 2.68****DRAT. See discount rate adjustment
technique****E****EARLY DEVELOPMENT****PHASE Exhibit 2-1 at 2.68****ECONOMIC CASH FLOWS 6.39–41****ECONOMIC EARNINGS 1.14****ECONOMIC RENTS. See also contributory
asset charges 1.20****ELECTRONIC DEVICES****INDUSTRY 6.19–22****ENABLING TECHNOLOGY**

- Commonly considered basis of contributory
 asset charge 6.94
- Definition 6.51
- Generally 6.51–58
- Illustration 6.57
- Questions and answers 6.54–56

EPVT. See expected present value technique**EQUIPMENT COSTS 3.12****EQUITY METHOD INVESTMENT ... 2.66, 3.31****EXPECTED PRESENT VALUE TECHNIQUE**

(EPVT)

- Generally 6.02, 6.100–111
- Method 1 6.102–104
- Method 2 6.102–104

F**FACILITIES COSTS 3.12****FAIR VALUE**

- Definition of 6.04, 6.06
- Hierarchy 6.04

FAIR VALUE MEASUREMENT 6.03–78

- Comparison to fair value of other assets
 owned 6.132–138
- Comparison to overall fair
 value 6.132–138
- Cost approach. See cost approach to fair value
 of IPR&D assets
- Definition of fair value 6.04, 6.06
- Definition of highest and best use for
 nonfinancial assets 6.04, 6.15
- Definition of most advantageous
 market 6.04
- Definition of principal market 6.04
- Fair value hierarchy 6.04
- Framework for 6.04
- Impact of decision to abandon R&D
 efforts on 2.67
- Impact of receiving results of clinical or
 other R&D efforts subsequent to
 acquisition date but before end of
 measurement period 2.68
- Income approach. See income approach to fair
 value of IPR&D assets
- Indefinite-lived IPR&D assets 4.19–22
- Intangible assets 6.122, 6.123
- IPR&D asset 1.01–34, 6.79–138,
 6.151
- Market approach. See market approach to fair
 value of IPR&D assets
- Measurement period 2.65
- Relative to other assets acquired and overall
 purchase price 6.132–138
- Valuation techniques 1.01–34, 6.04

FINANCIAL BUYERS 6.13**FINANCIAL INFORMATION. See prospective
financial information (PFI)****FIXED ASSETS**

- Commonly considered basis of contributory
 charge 6.94
- Contributory asset charges 6.86
- Valuation example 6.199, Schedule 6-12

FORECAST 6.27**FUNCTIONALITY 6.62****FUTURE CASH FLOWS**

- Estimates 4.64
- Used in recoverability testing of held
 and used assets resulting from R&D
 activities 4.60–68

FUTURE R&D 6.62**FUTURE TECHNOLOGY 6.59, 6.62****FUTURE YET-TO-BE-DEFINED****TECHNOLOGY 6.59****G****GOODWILL**

- In asset acquisitions 3.10
- Contribution for elements of 6.96
- Generally 2.09

GREENFIELD METHOD	1.34
GROUPING	4.58–59

H**HELD AND USED ASSETS**

- Estimating future cash flows used in recoverability testing of 4.60–68
- Grouping 4.58–59
- Impairment loss related to 4.69–70, 4.73
- Impairment model 4.53
- Impairment testing 4.54–73
- Order of impairment testing 4.71–72

HELD FOR SALE ASSETS

- Classifying 4.74–75
- Criteria for classifying 4.74–75
- Definition of 2.28
- Impairment model 4.53, 4.76
- Impairment testing 4.74–79
- Order of impairment testing 4.77–79

HISTORY, COMPANY	6.38
-------------------------------	-------------

I

IDLED ASSETS	2.10
---------------------------	-------------

IMPAIRMENT LOSS

- Held and used assets resulting from R&D activities 4.69–70, 4.73
- Indefinite-lived IPR&D assets 4.23

IMPAIRMENT MODELS

- Assets held and used 4.53
- Assets held for sale 4.53
- Held for sale assets resulting from R&D activities 4.76
- Indefinite-lived IPR&D assets 4.15–31

IMPAIRMENT TESTING

- Assets resulting from R&D activities 4.51–73
- Held and used assets resulting from R&D activities 4.54–73
- Held for sale assets resulting from R&D activities 4.74–79
- Indefinite-lived IPR&D assets 4.10–14

INCOME

- Fair value measurement application 1.14

INCOME APPROACH TO FAIR VALUE OF IPR&D ASSETS

- Applications 1.04
- Basic steps 1.14
- Decision tree analysis 1.25–26
- Generally 1.13–34, 6.122
- Intangible assets 6.122–123
- Items to include in valuation report 6.181–182
- Monte Carlo analysis 1.28
- Most commonly used methods and techniques 1.16
- Multiperiod excess earnings method. See multiperiod excess earnings method

INCOME APPROACH TO FAIR VALUE OF IPR&D ASSETS—continued

- Options-based methods 1.29–30
- Other methods and techniques that might be used 1.17
- Relief from royalty method. See relief from royalty method
- Single-period capitalization 1.15
- Split methods 1.16, 1.27

INCOME TAX

- Benefits from amortization of IPR&D assets for income tax purposes 6.122–131
- Deferred tax calculation 4.82
- Valuation allowance assessments ... 4.80–81

INCOMPLETENESS	2.36
-----------------------------	-------------

INCREMENTAL REVENUE OR PROFIT ...	1.32
--	-------------

INDEFINITE-LIVED IPR&D ASSETS

- Abandonment of associated R&D efforts 4.14, 4.24–29
- Accounting, compared to accounting for assets resulting from R&D activities 4.07–08
- Changes in facts and circumstances 4.12–13
- Completion of associated R&D efforts ... 4.14
- Fair value determination of 4.19–22
- Generally 4.02
- Impairment loss related to 4.23
- Impairment model 4.15–31
- Impairment testing of 4.10–14
- Outlicensing arrangements 4.30–31
- Qualitative assessment of 4.15–17
- Quantitative impairment test 4.18

INDUSTRY FACTORS	6.38
-------------------------------	-------------

IN-PROCESS R&D (IPR&D) ASSETS

- Amortization for income tax purposes 6.122–131, 6.150
- Asset acquisitions 3.10
- Business combination acquisitions. See business combinations, assets acquired in
- Completion and readiness for intended use 4.33–36
- Contingent considerations 6.02
- Decision tree analysis 6.154–170
- Defensive 2.10, 2.29–33, 6.19–25
- Definition of 2.03, 3.08
- Disclosures 5.03
- Fair value measurement 1.01–34, 6.79–138, 6.151
- Identification and description of 6.176
- Income tax considerations 4.80–82
- Indefinite-lived. See indefinite-lived IPR&D assets
- PFI related to 6.48–78
- Pharmaceutical (example) 6.155–168
- Relief from royalty 6.139–153
- Sample footnote disclosures 5.04, 5.10
- Subsequent accounting 4.01–86
- Temporarily idled or abandoned 2.34–35

IN-PROCESS R&D (IPR&D)**ASSETS—continued**

- That will continue to be pursued 6.19–25
- Unit of account 2.18–24
- Useful lives of 3.10
- Valuation. See valuation of in-process R&D (IPR&D) assets
- Valuation allowance assessments ... 4.80–81

IN-PROCESS R&D (IPR&D) PROJECTS

- Acquired 2.16–17
- Conceptualization of 2.45
- Definition of 2.03, 3.08
- Development of 2.45
- Incompleteness of 2.54–63
- Life cycle 2.44–47
- R&D expenses attributable to 6.74
- Substance 2.48–53
- Tax expenses attributable to 6.74
- Technical support expenses attributable to 6.74
- Valuation example 6.195–197, 6.199, Schedule 6-6

INTANGIBLE ASSETS

- Acquired for use in R&D activities ... 4.01–86, 5.04
- Completed 2.36–37
- Contributory asset charges 6.86
- Contributory charge 6.94
- Defensive 2.30
- Fair value measurement 6.122
- Not used in R&D activities 2.11–13
- Purchased from others 3.12
- Required levels 6.35
- Sample footnote disclosures 5.04
- Used in R&D activities 2.10, 2.36–37

INTERNAL RATE OF RETURN (IRR)

- Derivation of 6.113
- Example calculation 6.131
- Generally 6.114
- Relationship with WACC 6.115
- Valuation example 6.199, Schedule 6-10

INVESTMENT 2.66, 3.31**IPR&D. See in-process R&D****J****JOINT VENTURES 2.66****M****MANAGEMENT DISCUSSION AND ANALYSIS (MD&A)**

- Assets acquired for use in R&D activities 5.05–07

MANUFACTURING COST SAVINGS 1.31**MARKET APPROACH TO FAIR VALUE OF IPR&D ASSETS**

- Applications 1.04
- Generally 1.10–12, 6.180
- Items to include in valuation report 6.179

MARKET PARTICIPANTS

- Assumptions of 6.42–47
- Characteristics 6.06
- Definition of 6.04
- Factors to consider 6.10
- Identification of 6.06–14, 6.19–25

MARKETING EXPENSE 6.35**MARKETS**

- Active 6.04
- Principal (or most advantageous) 6.04

MATERIALS COSTS 3.12**MONTE CARLO ANALYSIS 1.28, 6.182****MULTIPERIOD DISCOUNTED CASH FLOW****METHOD 1.15****MULTIPERIOD EXCESS EARNINGS METHOD**

- Examples 6.137–138, 6.165, 6.193, 6.195, 6.199
- Generally 1.15–16, 1.20, 6.79–81
- Overlapping revenues 6.133–136
- Step 1: apply contributory asset charges for assets that contribute to generation of cash flows 6.82–98
- Step 2: calculate present value of cash flows using discount rate appropriate for specific IPR&D asset being valued 6.99–121
- Step 3: compute and add related income tax benefits resulting from amortization of IPR&D asset for income tax purposes 6.122–131
- Step 4: compare asset fair value to that of other assets acquired and overall purchase price or to overall fair value 6.132–138

N**NET CASH FLOWS**

- Definition of 1.14
- Present value and related probabilities examples 6.157–160

NET WORKING CAPITAL 6.35**NONFINANCIAL ASSETS**

- Definition of 6.15
- Highest and best use for 6.04, 6.15–25

O**OPERATING EXPENSES 6.35****OUTLICENSING 2.10****OUTLICENSING ARRANGEMENTS**

- Generally 2.10
- For indefinite-lived IPR&D assets 4.30–31

P**PATENTS**

- Commonly considered basis of contributory asset charge 6.94
- Valuation example 6.189–190, 6.199, Schedule 6-3

PHARMACEUTICAL INDUSTRY

- Assets acquired for use in R&D activities 5.04
- Phases of development Exhibit 2-1 at 2.68
- Sample footnote disclosures 5.04
- Valuation of IPR&D assets 6.23–25
- Valuation of IPR&D assets (example) 6.155–168

PHARMACEUTICAL PRODUCTS AND PROCESSES

- Example IPR&D assets valuation 6.155–168
- Phases of development Exhibit 2-1 at 2.68
- Related to right to market or use that are subject to governmental regulations 2.57

POSTMARKETING SURVEILLANCE**TRIALS Exhibit 2-1 at 2.68****PREPRODUCTION PHASE 2.45****PRESENT VALUE**

- After-tax cash flows 6.148–149
- Cash flows 6.99–121

PRIMARY ASSETS 4.65**PRINCIPAL (OR MOST ADVANTAGEOUS) MARKET 6.04****PROBABILITY FACTORS 6.38****PRODUCT PHASE Exhibit 2-1 at 2.68****PROJECTION 6.27****PROSPECTIVE FINANCIAL INFORMATION (PFI) 6.26–78**

- Comparing to PFI attributable to IPR&D assets 6.75–78
- Contributions from technology subcomponents 6.53
- Development of 6.42–47
- Ensuring assumptions are consistent with those of market participants 6.42–47
- Evaluating and documenting key assumptions relating to 6.33–41
- Examples 6.45–47
- Expenses that may need to be reflected in 6.74
- Generally 6.26–27
- IPR&D asset-related 6.48–78
- Selection of 6.28–32
- Sources of 6.28
- Step 1: selection 6.28–32
- Step 2: evaluation and documentation of key assumptions 6.33–41
- Step 3: ensuring assumptions are consistent with those of market participants 6.42–47
- Step 4: comparing PFI attributable to IPR&D assets to PFI for overall entity 6.75–78
- Step 4: isolating IPR&D asset-related PFI 6.48–74

Q**QUALITATIVE ASSESSMENT 4.15–17****QUANTITATIVE IMPAIRMENT TEST 4.18****R****REAL OPTIONS 1.29, 6.182****REAL OPTIONS ANALYSIS 1.29–30****RECOVERABILITY TESTING 4.60–68****REGULATORY ENVIRONMENT FACTORS 6.38****RELIEF FROM ROYALTY****METHOD 6.139–153**

- Examples 6.152, 6.199
- Generally 1.05, 1.21–24, 6.139–141
- Insufficient observable royalty translations 6.153
- Step 1: isolate prospective revenue stream related to subject asset 6.142–143
- Step 2: determine appropriate hypothetical royalty rate for use of subject asset 6.144–147
- Step 3: calculate present value of after-tax cash flows using discount rate appropriate for specific asset being valued 6.148–149
- Step 4: compute related income tax benefits resulting from amortization of IPR&D asset for income tax purposes 6.150
- Step 5: evaluate overall reasonableness of IPR&D asset fair value relative to other assets acquired and overall purchase price 6.151

REPLACEMENT COST 1.07**RESEARCH AND DEVELOPMENT (R&D)**

- Abandonment of efforts 2.67, 4.14, 4.24–29
- Assets used in. See assets
- Completion of 4.14, 4.33–36
- Discovery research phase Exhibit 2-1 at 2.68
- Early development phase Exhibit 2-1 at 2.68
- Future technology 6.62
- In-process. See in-process R&D (IPR&D) projects
- Phases of development Exhibit 2-1 at 2.68
- Postmarketing surveillance trials Exhibit 2-1 at 2.68
- Product phase Exhibit 2-1 at 2.68
- Results subsequent to acquisition date but before end of measurement period 2.68
- Scope of activities 2.39–43
- Time to complete, factors to consider ... 6.38

RESEARCH AND DEVELOPMENT (R&D) COSTS 3.12**RESEARCH AND DEVELOPMENT (R&D)****EXPENSE**

- Attributable to IPR&D 6.74
- Generally 6.35

RETURN OF THE OVERALL ENTITY 6.112–121

RETURN ON ASSETS. *See* **weighted average return on assets (WARA)**

REVENUE

- Generally 6.35
- Valuation example 6.199, Schedule 6-9

ROYALTY. *See* **relief from royalty method**

S

SALES AND MARKETING EXPENSE 6.35

SINGLE PERIOD CAPITALIZATION METHOD 1.15

SOFTWARE TO BE SOLD, LICENSED, OR OTHERWISE MARKETED 2.57

STRATEGIC BUYERS 6.13

SURVEILLANCE TRIALS Exhibit 2-1 at 2.68

T

TAB. *See* **tax amortization benefits**

TANGIBLE ASSETS

- Required levels 6.35
- Used in R&D activities 2.38

TANGIBLE PRODUCTS 2.57

TAX AMORTIZATION BENEFITS (TAB)

- Contributory asset charges 6.97
- Effect on WARA in taxable vs nontaxable transactions 6.130
- Formula for calculating 6.125
- IPR&D assets, computing and adding 6.122–131, 6.150

TAX EXPENSES 6.74

TAX RATES 4.82

TAXES, INCOME. *See* **income tax**

TECHNICAL SUPPORT EXPENSES 6.74

TECHNOLOGY

- Core or base 2.25–28, 6.58
- Developed. *See* **developed product technology**
- Enabling 6.51–58, 6.94
- Factors to evaluate 6.62
- Future 6.59, 6.62
- Future yet-to-be-defined 6.59
- Subcomponents 6.63–64

TECHNOLOGY COMPANIES 5.04

TECHNOLOGY MIGRATION

- Definition of 6.59
- Example 6.66–74
- Generally 6.59–74

TEMPORARILY IDLED OR ABANDONED ASSETS 2.34–35

TRADE NAMES

- Commonly considered basis of contributory asset charge 6.94
- Valuation example 6.187–188, 6.199, Schedule 6-2

TRADEMARKS 6.94

TRADITIONAL TECHNIQUE. *See* **discount rate adjustment technique (DRAT)**

TRANSACTION COSTS 3.10

TRANSACTIONS. *See* **asset acquisitions; business combinations**

U

UNIT OF ACCOUNT 2.18–24

- Determination of 2.21–24
- Factors to consider 2.20–21

UNOBSERVABLE INPUTS

- Fair value hierarchy 6.04
- Generally 6.08

V

VALUATION ALLOWANCE ASSESSMENTS 4.80–81

VALUATION METHODS. *See* **valuation techniques**

VALUATION OF IN-PROCESS R&D (IPR&D) ASSETS 6.01–199

- Comparison to other assets acquired and overall purchase price 6.151
- Considerations related to FASB ASC 820 6.03–78
- Electronic devices industry 6.19–22
- Example, comprehensive 6.185–199
- Generally 6.01–02
- Pharmaceutical industry 6.23–25
- Reports. *See* **valuation reports**
- Techniques for. *See* **valuation techniques**
- Use of PFI 6.26–78

VALUATION REPORTS 6.173–184

- Comprehensive example 6.199, Schedules 6-1–6-12
- Generally 6.173–175
- Identification and description of IPR&D assets 6.176
- Reconciliation of value estimates 6.184
- Summary of Assets 6.199, Schedule 6-11
- Supporting schedules 6.199, Schedule 6-12
- Valuation of IPR&D assets 6.177–183
- Valuation Summary 6.199, Schedule 6-1

VALUATION TECHNIQUES 1.01–34

- Classification of 1.05
- Cost approach. *See* **cost approach to fair value of IPR&D assets**

VALUATION TECHNIQUES—continued

- Definition of 1.01, 6.04
- Income approach. See income approach to fair value of IPR&D assets
- Market approach. See market approach to fair value of IPR&D assets
- Other methods 6.171–.172

W

WACC. See **weighted average cost of capital**

WARA. See **weighted average return on assets**

WEIGHTED AVERAGE COST OF CAPITAL (WACC)

- Generally 6.95
- Reconciliation with WARA 6.120
- Relationship with IRR 6.115

WEIGHTED AVERAGE RETURN ON ASSETS (WARA)

- Calculation of 6.118
- Illustrative calculation 6.119
- Reconciliation with WACC 6.119
- TAB effect on 6.130
- Valuation example 6.199, Schedule 6-12

"WITH AND WITHOUT" ANALYSIS 1.33**WORKFORCE**

- Commonly considered basis of contributory asset charge 6.94
- Valuation example 6.199, Schedule 6-7

WORKING CAPITAL

- Commonly considered basis of contributory asset charge 6.94
- Contributory asset charges 6.86
- Net working capital 6.35

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>